BEYOND TRANSPARENCY: THE $4 DOLLAR EFFECT

Using the four dollar generic program in a transparent, Full Pass-through PBM Model to drive rapid reduction in cost to Payors & members
First, this case study will seek to highlight the impact of the $4 generic program, which has growing enthusiasm with payors, and has been applied to a Health Plan in the Midwest with [...]

Antibiotic Resistance: Who’s Fault is it Anyway?

I’ve been preaching about the misuse of antibiotics for years, and the public at large is finally getting the message. “Antibiotic resistance and superbugs such as MRSA,” I’d say with the utmost conviction, “is due to so many unnecessary prescriptions for viral colds and flu!” That sounds familiar right? That’s what they taught us to [...]

Who was Jim Howe?

Results revealed next week.

Terms of Use

Welcome to Rx Times!
Please read these Terms of Use and the accompanying Privacy Policy carefully before using the website and/or submitting any personal information that could identify you (including but not limited to name, address, telephone number and email address).
By using the website, you signify your agreement to these Terms of Use and the Privacy [...]

Advertising

Reach Your Target Audience Effectively
RxTimes.com effectively reaches a large, loyal and growing audience of decision-making professionals by granting access, through a single site, to multiple voices. RxTimes endless store of industry articles leads to longer session times and increased impressions for the advertiser.
If you are interested in building major brand appeal, we offer distinct advantages, [...]

Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease

CRANBURY, N.J., Oct. 2 — Amicus Therapeutics (Nasdaq: FOLD) today announced preliminary results from its Phase 2 randomized, open-label study to assess the safety, tolerability and preliminary efficacy of its investigational drug, Plicera(TM) (afegostat tartrate), in treatment-naive adult patients with type 1 Gaucher disease. Two dose regimens of Plicera (225 mg three days on/four days [...]

Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers

CALGARY, Oct. 2  – Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and [...]

Sanofi Pasteur Announces Results of U.S. Clinical Trials in Adults Following One Dose of Influenza A (H1N1) Vaccine

LYON, France and SWIFTWATER, Pa., Oct. 1  – Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults 18 years through 64 years of age and over the age [...]

Newly published Phase III data show Novartis drug Sandostatin® LAR Depot reduced risk of disease progression by 66% in advanced NET patients

East Hanover, N.J. (October 1, 2009) — Data published in the Journal of Clinical Oncology show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) experienced a 66% reduction in risk of disease progression versus placebo1. Sandostatin LAR is indicated to treat [...]

Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer

WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30  — Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a randomized, placebo-controlled Phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agent, paclitaxel, in patients with locally advanced or metastatic HER-2 negative breast [...]

Next Page »